Molecular Formula | C36H63N11O8 |
Molar Mass | 777.95 |
Appearance | powder |
Color | white |
Storage Condition | -20°C |
In vitro study | 2-Furoyl-LIGRLO-amide (2-Furoyl-LIGRLO-NH 2 ) is equally effective to and 10 to 25 times more potent than SLIGRLNH 2 for increasing intracellular calcium in cultured human and rat PAR2-expressing cells, respectively. In bioassays of tissue PAR2 activity, measured as arterial vasodilation and hyperpolarization, 2-Furoyl-LIGRLO-amide (2-Furoyl-LIGRLO-NH 2 ) is 10 to 300 times more potent than SLIGRL-NH 2 . Unlike trans-cinnamoyl-LIGRLO-NH 2 , 2-Furoyl-LIGRLO-amide do not cause a prominent non-PAR2-mediated contraction of murine femoral arteries. |
In vivo study | Furoyl-LIGRLO-amide (injected intradermally at the nape of the neck; 10 μg; pre-injected) exhibits fewer scratches in response to 2-Furoyl-LIGRLO-amide but not to histamine in Trpv3 -/- mice. But it decreases significantly the number of scratches in WT mice. Animal Model: Adult male (2/3-month-old) Trpv3 -/- and WT mice Dosage: 10 μg Administration: Injected intradermally at the nape of the neck Result: Was involved in PAR2- induced acute itch. |
Hazard Symbols | Xi - Irritant![]() |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
biological activity | 2-Furoyl-LIGRLO-amide is a potent selective protease-activated receptor 2 (PAR2) agonist with a pD2 value of 7.0. |
target | Proteinase-activated receptor 2 (PAR2) |
in vitro study | 2-furoyl-ligro-amide (2-furoyl-ligro-nh2) is equally effective to and 10 to 25 times more potent than SLIGRLNH 2 for increasing intracellular calcium in cultured human and rat PAR2-expressing cells, respectively. In bioassays of tissp2 activity, measured as arterial vasodilation and hyperpolarization, 2-furoyl-ligro-amide (2-furoyl-ligro-nh2) is 10 to 300 times more than SLIGRL-NH 2 . Unlike trans-cinnamoyl-LIGRLO-NH 2, 2-furoyl-ligrlo-amide do not cause a prominent non-PAR2-mediated contraction of murine femoral arteries. |
in vivo research | Furoyl-LIGRLO-amide (injected intradermally at the neck of the neck; 10 μg; pre-injected) exhibits fewer scratches in response to 2-furoyl-ligrlo-amide but not to histamine in trpv3-/- mice. but it decreases significantly the number of scratches in wtmice. animal model: adult male (2/3-month-old) trpv3-/- and wtmice dosage: 10 μ g Administration: Injected intradermally at the nape of the neck result: was involved in PAR2- induced acute itch. |
Animal Model: | Adult male (2/3-month-old) Trpv3 -/- and WT mice |
Dosage: | 10 μg |
Administration: | Injected intradermally at the nape of the neck |
Result: | Was involved in PAR2- induced acute itch. |